High levels of DEPDC1B predict shorter biochemical recurrence‑free survival of patients with prostate cancer

Abstract

DEP domain-containing protein 1B (DEPDC1B) has been reported to serve important functions in breast cancer and non-small cell lung cancer. However, its involvement in the development of prostate cancer (PCa) remains unclear. Therefore, the present study aimed to investigate the expression and clinical significance of DEPDC1B in tumor tissues from patients diagnosed with PCa. A total of 80 prostate tissue samples were collected following prostatectomy to generate a tissue microarray for immunohistochemical analysis of DEPDC1B protein expression. High throughput sequencing of mRNAs from 179 prostate tissue samples, either from patients with PCa or from healthy controls, was included in the Taylor dataset. The expression levels of DEPDC1B in tumor tissues from patients with PCa were revealed to be significantly increased compared with those in normal prostate tissues (P=0.039). Increased expression of DEPDC1B was significantly associated with advanced clinical stage (P=0.006), advanced T stage (P=0.012) and lymph node metastasis (P=0.004). Kaplan-Meier analysis demonstrated that patients with high levels of DEPDC1B mRNA had significantly shorter biochemical recurrence (BCR)-free survival times. Multivariate analysis using Cox proportional hazards model revealed that levels of DEPDC1B mRNA were significant independent predictors of BCR-free survival time of patients with PCa. Therefore, the expression of DEPDC1B may be used as an independent predictor of biochemical recurrence-free survival time of patients with PCa.

Establishment of rat anti-canine DEP domain containing 1B (DEPDC1B) monoclonal antibodies

“…In contrast, the sections were positively stained with monoclonal antibody clones #4and #13. DEPDC1B protein was located in the cytoplasm in the sections stained with clones #4 and #13, which was consistent with human studies [1,11]. However, the with anti-DEPDC1B monoclonal antibody #4 (Fig.…”

“…Although DEPDC1B protein has been analyzed extensively in human studies [1,2,5,7,10,12], there are no reports about DEPDC1B expression in dogs, partly due to the lack of a specific monoclonal antibody against canine DEPDC1B. Some of the monoclonal antibodies established in the present study, particular clone #4, are promising for the analysis of canine DEPDC1B.…”

“…The correlation between the protein expression levels of DEPDC1B and cancer progression has been described recently in human prostate cancer, non-small cell lung cancer, and malignant melanoma [1,11,12]. A tissue microarray of DEPDC1B in 73 prostate cancers demonstrated that high expression levels of DEPDC1B were significantly associated with advanced clinical stages [1]. DEPDC1B…”

“…Marchesi S. et al showed that DEPDC1B accumulates in G2 phase of the cell cycle and controls entry into mitosis through the modulation of cell adhesion and actin cytoskeleton dynamics [6]. In addition, DEPDC1B has been reported to be overexpressed and associated with tumor cell migration, invasion, and tumor growth in various types of human cancers such as breast cancer [2], prostate cancer [1], non-small cell lung cancer [12], and malignant melanoma [11]. However, in dogs, the expression and the function of DEPDC1B remains largely unknown.…”

“…section stained with clone #13 showed weaker positive staining compared with the section stained with clone #4 (data not shown). Referring to human studies for the detectability of DEPDC1B protein[1,11], we selected clone #4 as an antibody suitable for immunohistochemical staining. Moreover, to assess the DEPDC1B expression in a canine T cell lymphoma tissue, a normal lymph node, and a normal kidney tissue, immunohistochemistry was performed using monoclonal antibody #4 (5 μg/ml final concentration) or normal rat IgG2b (Santa Cruz Biotechnology) as an isotype control.…”